AI10 Stock Overview
A biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Biofrontera Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.74 |
| 52 Week High | US$25.00 |
| 52 Week Low | US$7.26 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | 4.06% |
| 1 Year Change | -51.30% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -84.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| AI10 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | 0.6% |
| 1Y | -51.3% | -19.9% | 3.3% |
Return vs Industry: AI10 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: AI10 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| AI10 volatility | |
|---|---|
| AI10 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: AI10 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine AI10's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 81 | Hermann Luebbert | www.biofrontera-us.com |
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription drug for the treatment of impetigo.
Biofrontera Inc. Fundamentals Summary
| AI10 fundamental statistics | |
|---|---|
| Market cap | €11.35m |
| Earnings (TTM) | -€21.44m |
| Revenue (TTM) | €27.47m |
0.4x
P/S Ratio-0.5x
P/E RatioIs AI10 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AI10 income statement (TTM) | |
|---|---|
| Revenue | US$29.05m |
| Cost of Revenue | US$14.97m |
| Gross Profit | US$14.08m |
| Other Expenses | US$36.75m |
| Earnings | -US$22.67m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -16.57 |
| Gross Margin | 48.47% |
| Net Profit Margin | -78.03% |
| Debt/Equity Ratio | 15.4% |
How did AI10 perform over the long term?
See historical performance and comparison